Private startupCompany profile · informational
NewLimit
NewLimit develops epigenetic reprogramming medicines intended to restore youthful function to aged cells, starting with liver cells. It was co-founded by Brian Armstrong, Blake Byers and Jacob Kimmel and plans its first human trial in 2027.
Verified highlights each with its source
- NewLimit announced a $435 million Series C led by Founders Fund on June 2, 2026 (company blog).
Source: blog.newlimit.com ↗ - The company plans a first human clinical trial of a hepatocyte (liver) reprogramming medicine in 2027.
Source: blog.newlimit.com ↗
Sources
- statnews.comstatnews.com
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
